ArticleBMC pulmonary medicine2026
Transbronchial lung cryobiopsy in fibrotic hypersensitivity pneumonitis: prognostic differences and intra-lobar variability.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransbronchial lung cryobiopsy (TBLC) is increasingly used to diagnose interstitial lung disease; however, its diagnostic accuracy for fibrotic hypersensitivity pneumonitis (HP) remains uncertain. We aimed to compare disease progression between patients with fibrotic HP diagnosed by TBLC-based multidisciplinary discussion (TBLC-MDD) and those diagnosed by surgical lung biopsy-based MDD (SLB-MDD).
methodsThis single-center retrospective study included patients diagnosed with fibrotic HP via MDD between January 2005 and June 2023. Histopathological findings-chronic fibrosing interstitial pneumonia, airway-centered fibrosis, and poorly formed nonnecrotizing granulomas-were assessed using the 2020 ATS/JRS/ALAT HP guidelines. For SLB-MDD patients who underwent TBLC prior to SLB, changes in diagnostic confidence were evaluated. To compare overall survival (OS) between the TBLC-MDD and SLB-MDD groups, 1:1 propensity score matching was performed. OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models.
resultsHistopathological features were significantly less prevalent in TBLC than in SLB specimens. In the first lower-lobe specimen, chronic fibrosing interstitial pneumonia was identified in 26% of TBLC compared to 89% of SLB specimens (p < 0.001). Among 31 SLB-MDD patients with prior TBLC, SLB significantly improved diagnostic confidence in 26 patients (84%; p < 0.001). After propensity score matching (96 pairs), TBLC-MDD patients showed significantly better OS than SLB-MDD patients (HR, 0.436; 95% CI, 0.197-0.963; p = 0.035). Within the TBLC-MDD group, concordance for chronic fibrosing interstitial pneumonia between the first and second lower-lobe specimens was poor (κ = 0.092). The presence of chronic fibrosing interstitial pneumonia in the second lower-lobe specimen independently predicted mortality (HR, 3.233; 95% CI, 1.115-9.376; p = 0.031), whereas findings from the first lower-lobe specimen were not statistically significant.
conclusionsPatients with fibrotic HP diagnosed by TBLC-MDD exhibited a more favorable prognosis than those diagnosed by SLB-MDD, likely due to insufficient subpleural sampling by TBLC. TBLC should be considered a complementary diagnostic tool to SLB for fibrotic HP, and its interpretative limitations might be carefully addressed during MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.